Actualités Pharming Group NV - PHAR | Actions NASDAQ

Outils de qualité professionnelle, pour des investisseurs individuels.

Notice of Full Year 2022 financial results

Notice of Full Year 2022 financial results PR Newswire LEIDEN, Netherlands, Feb. 28, 2023 LEIDEN, Netherlands...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 6-KREPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE 13a-16 OR...

Pharming announces first patient enrolled in pediatric clinical trial of leniolisib

Pharming announces first patient enrolled in pediatric clinical trial of leniolisib PR Newswire LEIDEN...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 6-KREPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE 13a-16 OR...

Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe

Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe PR Newswire LEIDEN...

Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

Pharming announces positive interim analysis data from open-label extension study of leniolisib in...

Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib

Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Pharming Group NV (PHAR)

Outils de qualité professionnelle, pour des investisseurs individuels.

PHAR Actualités

Notice of Full Year 2022 financial results

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Pharming announces first patient enrolled in pediatric clinical trial of leniolisib

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe

Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood

Pharming Group announces presentation of new leniolisib data at 2022 ASH Annual Meeting

Pharming to present at Jefferies Healthcare Conference

Pharming to present at Stifel Healthcare Conference

Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Pharming Group NV (PHAR) Actualités

Pharming Group NV (PHAR)

Outils de qualité professionnelle, pour des investisseurs individuels.

PHAR Actualités

Notice of Full Year 2022 financial results

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Pharming announces first patient enrolled in pediatric clinical trial of leniolisib

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe

Pharming announces positive interim analysis data from open-label extension study of leniolisib in presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood

Pharming Group announces presentation of new leniolisib data at 2022 ASH Annual Meeting

Pharming to present at Jefferies Healthcare Conference

Pharming to present at Stifel Healthcare Conference

Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application